Immunotherapy Archives

medical cancer checkpoint inhibitor immunotherapy

News and Trends 29 Apr 2021

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […]

April 29, 2021 - 5 minutesmins - By Mark Zipkin

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major […]

April 15, 2021 - 5 minutesmins - By Mark Zipkin

VC finance stock funds ipo gamma delta t cell lava therapeutics

News and Trends 31 Mar 2021

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with an €85.6M ($100.5M) IPO. This is a sign of mounting investor interest in cancer treatments based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s […]

March 31, 2021 - 5 minutesmins - By Anita Chakraverty

News and Trends 25 Mar 2021

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

The rise of adenoviral Covid-19 vaccines highlights the potential of companies using similar technology in other fields like cancer or gene therapy. However, complex challenges remain, such as circumventing immunity to adenoviral treatments. Earlier this month, Johnson & Johnson’s candidate became the first single-shot Covid-19 vaccine to get the EMA green light. The vaccine is […]

March 25, 2021 - 6 minutesmins - By Victor Kotsev

In Depth 22 Mar 2021

Can Immunotherapy Offer Hope for Parkinson’s Sufferers?

Despite decades of research, effective treatments for Parkinson’s disease are proving elusive. Could immunotherapy finally provide a solution? More than seven million people worldwide are currently living with Parkinson’s disease, an incurable neurodegenerative disorder. Current treatment options are limited as they only attempt to mask the symptoms rather than address the cause. But there is […]

March 22, 2021 - 5 minutesmins - By David Cox

News and Trends 26 Jan 2021

Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms

Since the debut of Imlygic in 2015, no other oncolytic virus cancer therapies have been approved by the FDA and EMA. However, we’re seeing the first signs that the Covid-19 pandemic may help the field get out of the rut. Earlier this month, the Oxford-based firm Theolytics raised €5.6M in a Series A round. This […]

January 26, 2021 - 7 minutesmins - By Jonathan Smith

In Depth 21 Dec 2020

Enemy or Valuable Ally? How Biotech Uses Viruses for Good

Taking advantage of the ability of viruses to manipulate life is opening new doors for the biotech industry. Once only seen as our enemies, viruses are fast becoming some of our most valuable allies. Viruses may not have the best public image, but to biotechnologists, there’s a lot to admire about them. These tiny molecular […]

December 21, 2020 - 7 minutesmins - By Farhan Mitha

News and Trends 16 Nov 2020

Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal

Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up an emerging trend of harnessing our innate immune system to treat cancer. According to the deal’s terms, Affimed will receive €51M upfront to license to Roivant a preclinical-stage antibody drug for several undisclosed types of cancer. Roivant will handle the […]

November 16, 2020 - 3 minutesmins - By Jonathan Smith

In Depth 6 Jul 2020

How Immuno-Oncology Contributes to the Fight Against Covid-19

As the Covid-19 pandemic sweeps the world, cancer research is proving a valuable resource for developing new treatments for infectious diseases by harnessing the power of the immune system. Despite the growing number of viral outbreaks of different sizes and severity we have observed in the past years, the infectious disease market is far behind […]

July 6, 2020 - 7 minutesmins - By Maya Chergova

News and Trends 3 Jun 2020

What Did European Oncology Players Offer at ASCO 2020?

Despite widespread clinical trial delays caused by the coronavirus pandemic, many oncology biotechs have been able to continue their fight against cancer. With advances in CAR T-cell therapies, cancer vaccines, RNA drugs, and more, European companies held a strong presence at the American Society of Clinical Oncology (ASCO) this year. The huge ASCO conference has […]

June 3, 2020 - 10 minutesmins - By Jonathan Smith

News and Trends 28 May 2020

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

Lyon-based biopharmaceutical company Tollys has closed a Series A funding round of €2.3M to bring its lead RNA immunotherapy candidate to clinical trials in people with bladder cancer. The round was closed on the basis of the company reaching preclinical proof-of-concept for the drug. It brings the total amount raised by Tollys to €6.4M since […]

May 28, 2020 - 2 minutesmins - By Laura Cowen

News and Trends 2 Apr 2020

iTeos Therapeutics’ Cancer Immunotherapy Boosted with €114M Funding

An oversubscribed Series B2 round has seen the biopharmaceutical company iTeos Therapeutics raise €114M, which will be used to advance the clinical development of its two lead cancer immunotherapies. The funds follow on from €65M raised by iTeos in Series B financing in 2018. Since then, the Belgian company has completed a phase I trial […]

April 2, 2020 - 3 minutesmins - By Laura Cowen

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us